BACKGROUND: Previous studies comparing laparoscopic-assisted to open gastrectomy (OG) for resectable gastric cancer were inexhaustive, so an updated meta-analysis was performed to clarify quality of life, patient satisfaction, safety and effectiveness associated with laparoscopic-assisted gastrectomy (LAG). METHODS: Pubmed, Embase, and The Cochrane Library were searched from inception to December 2015 for randomized controlled trials (RCTs) comparing LAG with OG for resectable gastric cancer. Relative risk (RR) and weighted mean difference (WMD) with 95% confidence intervals (CIs) were pooled with random-effects model. Furthermore, trial sequential analysis (TSA) was employed to indicate the credibility of pooled estimate. RESULTS: Fourteen RCTs totaling 2,307 gastric cancer patients (1,163 in laparoscopic and 1,144 in open) were included. Compared with OG, LAG showed higher patient satisfaction and quality of life, less blood loss, hospital stay and overall postoperative morbidity, and longer operating time, which were confirmed by TSA. LAG also accelerated time to first flatus, first walking and first intake and reduced frequency of analgesic administration and days of fever. There were no significant difference between the two groups in number of retrieved lymph nodes, mortality, recurrence, long-term overall survival and disease-free survival. CONCLUSION: For patients with resectable gastric cancer, LAG decreased blood loss, length of hospital stay and overall postoperative morbidity and improved postsurgical recovery. J. Surg. Oncol. 2016;113:756-767.
BACKGROUND: Previous studies comparing laparoscopic-assisted to open gastrectomy (OG) for resectable gastric cancer were inexhaustive, so an updated meta-analysis was performed to clarify quality of life, patient satisfaction, safety and effectiveness associated with laparoscopic-assisted gastrectomy (LAG). METHODS: Pubmed, Embase, and The Cochrane Library were searched from inception to December 2015 for randomized controlled trials (RCTs) comparing LAG with OG for resectable gastric cancer. Relative risk (RR) and weighted mean difference (WMD) with 95% confidence intervals (CIs) were pooled with random-effects model. Furthermore, trial sequential analysis (TSA) was employed to indicate the credibility of pooled estimate. RESULTS: Fourteen RCTs totaling 2,307 gastric cancerpatients (1,163 in laparoscopic and 1,144 in open) were included. Compared with OG, LAG showed higher patient satisfaction and quality of life, less blood loss, hospital stay and overall postoperative morbidity, and longer operating time, which were confirmed by TSA. LAG also accelerated time to first flatus, first walking and first intake and reduced frequency of analgesic administration and days of fever. There were no significant difference between the two groups in number of retrieved lymph nodes, mortality, recurrence, long-term overall survival and disease-free survival. CONCLUSION: For patients with resectable gastric cancer, LAG decreased blood loss, length of hospital stay and overall postoperative morbidity and improved postsurgical recovery. J. Surg. Oncol. 2016;113:756-767.
Authors: Francesco Guerra; Giuseppe Giuliani; Martina Iacobone; Paolo Pietro Bianchi; Andrea Coratti Journal: Surg Endosc Date: 2017-04-04 Impact factor: 4.584
Authors: Andreas Andreou; Sebastian Knitter; Sascha Chopra; Christian Denecke; Moritz Schmelzle; Benjamin Struecker; Ann-Christin Heilmann; Johanna Spenke; Tobias Hofmann; Peter C Thuss-Patience; Marcus Bahra; Johann Pratschke; Matthias Biebl Journal: J Gastrointest Surg Date: 2018-10-03 Impact factor: 3.452
Authors: Vivian E Strong; Ashley E Russo; Masaya Nakauchi; Mark Schattner; Luke V Selby; Gabriel Herrera; Laura Tang; Mithat Gonen Journal: Ann Surg Oncol Date: 2020-07-11 Impact factor: 5.344